about
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemiaGenetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiencyTrials in sickle cell diseaseIs routine molecular screening for common alpha-thalassaemia deletions necessary as part of an antenatal screening programme?Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia.Direct and simultaneous quantitation of 5-aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography-atmospheric pressure chemical ionization/tandem mass spectrometry.Use of splenic ultrasound: a new wave for immune thrombocytopenic purpura.Extracranial internal carotid arterial disease in children with sickle cell anemia.Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.The spleen and sickle cell disease: the sick(led) spleen.Global distribution of the CCR5 gene 32-basepair deletion.Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial.Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein.The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype)Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trialMorbidity pattern of sickle cell disease in India: a single centre perspective.Molecular analysis of the beta-globin gene cluster in the Niokholo Mandenka population reveals a recent origin of the beta(S) Senegal mutation.The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.Management of sickle cell disease in the community.Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate.The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment.Effects of o-vanillin on K⁺ transport of red blood cells from patients with sickle cell disease.Impact of acute chest syndrome on lung function of children with sickle cell disease.Inhibitors of second messenger pathways and Ca(2+)-induced exposure of phosphatidylserine in red blood cells of patients with sickle cell disease.The significance of inadequate transcranial Doppler studies in children with sickle cell disease.The population genetics of factor V Leiden (Arg506Gln)Role of calcium in phosphatidylserine externalisation in red blood cells from sickle cell patients.Identification of the Ca²⁺ entry pathway involved in deoxygenation-induced phosphatidylserine exposure in red blood cells from patients with sickle cell diseaseThe rationale for using hydroxycarbamide in the treatment of sickle cell disease.A retrospective analysis of outcome of pregnancy in patients with acute porphyria.Pandemic influenza A (H1N1) virus infections in children with sickle cell disease.Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype).Best practice guidelines on clinical management of acute attacks of porphyria and their complications.Born to clot: the European burden.The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.The genetic basis of the interaction between pyrimidine 5' nucleotidase I deficiency and hemoglobin E.Epstein-Barr virus-related post-transplant lymphoproliferative disorder with t(9;14)(p11-12;q32).Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia.Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of beta-thalassaemia trait.Changing pattern of hospital admissions of children with sickle cell disease over the last 50 years.
P50
Q24245574-10AD6F16-281A-4EEC-825A-A714B7B3C06BQ28190176-A302CD78-E04B-4FE4-88C4-EE85E9D319E1Q28218946-E0FC3245-0378-4FB1-9668-F2BDD6CD8C13Q28236269-97EBA6C7-803F-42DE-B82D-B56CCB3EDE19Q33367390-5C08C076-2E50-4600-A2BE-32AB538C9B80Q33456444-EA3C4780-1311-4E92-950A-F0F36980944AQ33491635-4ACDFA49-EF19-43A3-A590-D645F8907C08Q34032190-860E93F7-0E38-42BD-8F54-34E67863FC30Q34154888-45156FC2-7E75-4094-BF3A-723F031B92A3Q34421414-98B764D9-3648-4E32-AB41-8D6215E446DFQ34425080-A1EFE576-C3AA-4CCF-90A4-F861EAD2C6E6Q34516361-D36D5215-101F-4391-9958-44ABAEEC0B28Q34538761-2AF79D0A-78C9-4E04-815F-78DD943E937FQ34734929-1DF4B54B-493D-4807-8421-4A56F15348B9Q37246765-90F26E23-7C11-4AD2-9D98-B4CCFC79A25BQ37282699-328B1307-11E3-4DB0-8E6A-54B13FE24D05Q37360157-98577561-55BD-463D-9D4B-915CEAC6AF79Q38058894-0AB06C9C-E239-4672-901D-2893C5B3E301Q38194789-8B649905-94AA-4613-A6EA-001D71DF0FBFQ39110722-E41EDF11-1EFE-425A-AC7A-8DE28C8DD025Q39788896-9AB4AE23-27EF-4651-B461-1C9DF9F0507EQ40115251-60BBC356-6FEA-46E9-A956-5C1287BFABF6Q40474055-D6459B0E-B578-48A1-A693-8E74A4653C4AQ40867999-1C7AD1D5-FDF0-4D90-9159-17F6BDE3E81CQ41118652-5F53CE67-DF8E-4CFF-B842-4EBB15D23B88Q41290748-833D3BFF-EE9F-47B2-BC06-135AF09D1E6BQ41788615-31E688EA-AD8C-42B9-A72C-C8950CEDFC6BQ42177296-8E4BD72C-A5BE-4D89-A6EE-E9CF910C2DFFQ42708637-35EF199A-D0CC-4726-8BE4-6DF3A81BB4AEQ43010126-56F2B3BC-982C-4F0E-BFBE-B8F4BBB77603Q43124610-CD1BBB54-8973-45B5-A638-F28650A41C72Q43130414-5D527B5D-3DC7-4650-95E3-9EA5CA117A3BQ44290994-667B4AA7-9511-467B-A89D-EE11EE03F2E4Q44557476-90E34E53-877E-42FE-B271-93B41EFC6065Q44853513-053197D9-2361-4913-B06D-CCA3EB5EFA8DQ45167668-FC4F663F-1156-43D3-A9F7-A7E4353A9EE7Q45724971-5EEA60E3-448A-472D-82C4-C924685CB4F5Q45927476-ED229E3A-1471-4CBC-A6E9-35EEF6B4B69BQ46129260-E665C3C3-4A69-4115-86C1-90E1AE597342Q46133331-C2F24237-1029-465F-83DC-E40D72B01322
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David C. Rees
@ast
David C. Rees
@en
David C. Rees
@es
David C. Rees
@nl
David C. Rees
@sl
type
label
David C. Rees
@ast
David C. Rees
@en
David C. Rees
@es
David C. Rees
@nl
David C. Rees
@sl
prefLabel
David C. Rees
@ast
David C. Rees
@en
David C. Rees
@es
David C. Rees
@nl
David C. Rees
@sl
P1053
B-6789-2011
P106
P1153
16747741000
P21
P31
P3829
P496
0000-0003-3647-1050